Glossary and trial notes

This page keeps the dense terms and trial names in one place.

Use it as a companion page while reading the rest of the section.

Quick glossary

• ERα — the estrogen receptor that helps drive many ER-positive cancers

• SERM — a drug that blocks the estrogen receptor in breast tissue, such as tamoxifen

• SERD — a drug that blocks and degrades the estrogen receptor, such as fulvestrant

• Aromatase inhibitor — a drug that lowers estrogen production, such as letrozole, anastrozole, or exemestane

• CDK4/6 inhibitor — a drug that holds cells in G1 phase, such as palbociclib, ribociclib, or abemaciclib

• Autophagy — the cell's recycling process

• Autophagosome — the membrane pouch that carries cargo to be broken down

• LC3-II / p62 — common lab markers used to study autophagy

• mTOR — a central nutrient-sensing pathway that regulates growth and autophagy

• Senescence — a living but growth-arrested cell state

• SASP — inflammatory signals released by senescent cells

• Senolytic — a drug that aims to kill senescent cells

• Senomorphic — a drug that aims to calm SASP without necessarily killing the cell

• ESR1 mutation — a mutation that can activate the estrogen receptor even without normal estrogen input

• CYP19A1 — the aromatase gene

• Rb — the retinoblastoma protein that helps restrain cell-cycle entry

• AMPK — a cellular energy sensor with both pro-death and pro-survival roles depending on context

• AKT — a survival-signalling kinase downstream of several growth pathways

• GLUT1 — a glucose transporter often increased in resistant cells

Current trial themes

McGrath et al. (2024) point to a growing group of studies using hydroxychloroquine with endocrine or CDK4/6 treatment.

The broad aim is similar across them.

First, induce a treatment-stressed state.

Then, try to stop cancer cells from using autophagy as a shelter.

Trials highlighted in the review include:

• NCT03774472 — hydroxychloroquine, palbociclib, and letrozole in the pre-surgery setting

• ABBY / NCT04523857 — abemaciclib plus hydroxychloroquine for minimal residual disease in bone marrow

• PALAVY / NCT04841148 — hydroxychloroquine with or without palbociclib and avelumab to target dormant bone-marrow tumour cells

• CLEVER / NCT03032406 — hydroxychloroquine with or without everolimus in patients with disseminated bone-marrow cells

• NCT05953350 — hydroxychloroquine with high-dose palbociclib

The sequencing idea in one line

The authors' practical model is:

Antiestrogen or CDK4/6 pressure first → cells enter autophagy or senescence → autophagy blocker and/or senolytic added later

That is different from treating hydroxychloroquine as a general-purpose add-on.

The proposed value lies in timing.

The six big open questions from the review

1. Does autophagy keep reversibly senescent cells alive?

2. Can protective autophagy be blocked without harming the useful cytostatic effect of CDK4/6 treatment?

3. When is the best time to add a senolytic?

4. Can cleaner autophagy inhibitors be developed beyond chloroquine and hydroxychloroquine?

5. How do we measure autophagy inhibition in real patients, not just lab models?

6. Which marker best identifies the dangerous senescent cells linked to later metastatic relapse?

Bottom line

The terminology in this field gets dense quickly.

The core message stays simple.

ER-positive cells may survive first and resist later.

The trials now under way are testing whether that survival phase can be interrupted more deliberately.